Indaptus Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Indaptus Therapeutics Inc.
- Former names
- Intec Parent Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- INDP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001857044
- EIN
- 86-3158720
Board of directors
-
Anthony J. Maddaluna · DirectorSince 2023
- Since 2025
- Since 2026
- Since 2026
-
Hila Karah · DirectorSince 2023
-
Jeffrey A. Meckler · Director · Co-Chief Executive OfficerSince 2023
-
Jerome D. Jabbour · DirectorSince 2026
-
Mark John Gilbert · DirectorSince 2023
-
Matthew Charles McMurdo · DirectorSince 2026
-
Michael James Newman · Director · CSO and DirectorSince 2023
-
Qinglai Lu · DirectorSince 2026
-
Robert Martell · DirectorSince 2023
-
Roger Pomerantz · DirectorSince 2023
-
William B. Hayes · DirectorSince 2023
Chief executives
Jeffrey A. Meckler
· Co-Chief Executive Officer
Dates unknown
Director election results
Annual meeting of February 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.8%
-
98.8%
Board connections
9 of this board's directors also sit on 15 other boards.
- via Avraham Ben-Tzvi, David E. Lazar, David Natan and Matthew Charles McMurdo
- via Avraham Ben-Tzvi, David E. Lazar and David Natan
- via Avraham Ben-Tzvi, David E. Lazar and David Natan
- via Avraham Ben-Tzvi, David E. Lazar and David Natan
- via Avraham Ben-Tzvi and David E. Lazar
- via David E. Lazar and David Natan
- via Avraham Ben-Tzvi
- via William B. Hayes
- via Hila Karah
- via Roger Pomerantz
- via David E. Lazar
- via Jerome D. Jabbour
- via David E. Lazar
- via David Natan
- via Jeffrey A. Meckler
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 20, 2026 | Avraham Ben-Tzvi Director | Grant or award | +25,000 | — | — |
| Dec 22, 2025 | Sassi Nir Officer (Chief Financial Officer) | Grant or award | +26,758 | $2.03 | $54,319 |
| Dec 22, 2025 | Jeffrey A. Meckler Director, Officer (Co-Chief Executive Officer), 10% owner | Grant or award | +216,617 | $2.03 | $439,733 |
| Dec 22, 2025 | Linscott Walt Addison Officer (Chief Operating Officer) | Grant or award | +54,421 | $2.03 | $110,475 |
| Dec 22, 2025 | Michael James Newman Director, Officer (CSO and Director) | Grant or award | +52,204 | $2.03 | $105,974 |
| Jul 27, 2025 | Jeffrey A. Meckler Director, Officer (Chief Executive Officer) | Grant or award | +6,068 | $8.30 | $50,364 |
| Nov 25, 2024 | Jeffrey A. Meckler Director, Officer (CEO and Director) | Grant or award | +42,553 | $1.18 | $50,213 |
| Aug 8, 2024 | Jeffrey A. Meckler Director, Officer (CEO and Director) | Grant or award | +84,932 | $1.83 | $155,426 |
| Aug 14, 2023 | Anderson Glen R. 10% owner | Open-market purchase | +23,934 | $2.34 | $56,006 |
| Aug 11, 2023 | Anderson Glen R. 10% owner | Open-market purchase | +35,064 | $2.12 | $74,336 |
| Aug 10, 2023 | Anderson Glen R. 10% owner | Open-market purchase | +44,354 | $1.94 | $86,047 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.